Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management.

Autor: Benitez-Hidalgo O; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Suito Alcántara M; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Martinez Garcia MF; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Campoy D; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Olivera P; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Gironella Mesa M; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Juarez-Gimenez JC; Hospital Pharmacy Department Hospital Universitari Vall d'Hebron Barcelona Spain.

Publikováno v: Clinical case reports [Clin Case Rep] 2024 Feb 07; Vol. 12 (2), pp. e8121. Date of Electronic Publication: 2024 Feb 07 (Print Publication: 2024).

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

Autor: Dimopoulos M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Sanz RG; Hospital Universitario de Salamanca, Salamanca, Spain., Lee HP; Department of Haematology, Flinders Medical Centre, Adelaide, SA, Australia., Trneny M; 1st Department of Medicine, Faculty of Medicine 1, Charles University, General Hospital, Prague, Czech Republic., Varettoni M; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico, San Matteo, Pavia, Italy., Opat S; Monash Health and.; Department of Hematology, School of Clinical Sciences, Monash University, Clayton, VIC, Australia., D'Sa S; University College London Hospital Foundation Trust, London, United Kingdom., Owen RG; St James University Hospital, Leeds, United Kingdom., Cull G; Sir Charles Gairdner Hospital, Perth, WA, Australia.; Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia., Mulligan S; Royal North Shore Hospital, Sydney, NSW, Australia., Czyz J; Szpital Uniwersytecki nr 2, Dr Jana Biziela, Kujawsko-pomorskie, Bydgoszcz, Poland.; Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland., Castillo JJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Medical Oncology, Harvard Medical School, Boston, MA., Motta M; AO Spedali Civili di Brescia, Lombardia, Italy., Siddiqi T; City of Hope National Medical Center, Duarte, CA., Gironella Mesa M; Hospital Universitario Vall d'Hebrón, Barcelona, Spain., Granell Gorrochategui M; Hospital de La Santa Creu i Sant Pau, Barcelona, Spain., Talaulikar D; The John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia., Zinzani PL; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Istituto di Ematologia 'Seràgnoli,' Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italy., Askari E; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Grosicki S; Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland., Oriol A; Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain., Rule S; Plymouth Hospitals National Health Service (NHS) Trust, Derriford Hospital, Devon, United Kingdom., Kloczko J; Uniwersytecki Szpital Kliniczny w Bialymstoku, Podlaskie, Poland., Tedeschi A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Buske C; Comprehensive Cancer Center (CCC) Ulm, Universitätsklinikum Ulm, Baden-Württemberg, Germany., Leblond V; Clinical Hematology Department, Sorbonne University, Pitié Salpêtrière Hospital, Paris, France., Trotman J; Concord Repatriation General Hospital, Sydney, Concord, NSW, Australia.; Concord Repatriation General Hospital, Department of Haematology, University of Sydney, Concord, NSW, Australia., Chan WY; BeiGene USA, Inc., San Mateo, CA., Michel J; BeiGene Switzerland GmbH, Basel, Switzerland., Schneider J; BeiGene USA, Inc., San Mateo, CA., Tan Z; BeiGene (Beijing) Co., Ltd, Beijing, China., Cohen A; BeiGene USA, Inc., San Mateo, CA., Huang J; BeiGene USA, Inc., San Mateo, CA., Tam CS; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; St Vincent's Hospital, Fitzroy, VIC, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia; and.; Royal Melbourne Hospital, Parkville, VIC, Australia.

Publikováno v: Blood advances [Blood Adv] 2020 Dec 08; Vol. 4 (23), pp. 6009-6018.